Key result
Nimodipine significantly increased the effective rate of treatment (OR 3.21) and reduced the incidence of adverse reactions compared to routine treatment in patients with subarachnoid hemorrhage.
Why the study?
Subarachnoid hemorrhage is an uncommon and serious stroke subtype causing long-term disability, and the clinical effect of nimodipine needed investigation.
Does nimodipine improve the effective rate and clinical outcomes in patients with subarachnoid hemorrhage?
Meta-Analysis (n=882)
Does nimodipine improve the effective rate and clinical outcomes in patients with subarachnoid hemorrhage?
Odds Ratio: 3.21 (95% CI 2.25–4.58)
p-value: p=<0.001
In a meta-analysis of 10 RCTs, nimodipine significantly improved clinical effective rates, Glasgow Coma Scale scores, and middle cerebral artery blood flow velocity in patients with subarachnoid hemorrhage.
Supports nimodipine in subarachnoid hemorrhage; reinforces RCT evidence for improved effective rates and outcomes.
Background Subarachnoid hemorrhage (SAH) is an uncommon and serious subtype of stroke, which leads to the loss of the patient's ability to produce and live for many years. Objective To investigate the clinical effect of nimodipine in the treatment of SAH. Methods Electronic databases including China National Knowledge Infrastructure (CNKI), VIP, SinoMed, China Master's Theses Full-text Database (CMFD), China Doctoral Dissertations Full-text Database (CDFD), Cochrane Library, PubMed and Embase were searched from 2010 and 2021. All randomized controlled trials evaluating the efficacy of nimodipine in the treatment of SAH were included in our meta-analysis. The patients were divided into control group and treatment group. Meta-analysis was performed with Stata16.0 software. Results A total of 10 studies were included. Compared with the control group, the treatment group had higher effective rate (OR = 3.21, 95% CI: 2.25, 4.58; p < 0.001), and lower incidence of adverse reactions (OR = 0.35, 95% CI: 0.19, 0.67; p = 0.001). Before treatment, no significant differences were identified in middle cerebral artery blood flow velocity and Glasgow coma scale (GCS) score between the two groups. However, after treatment, the middle cerebral artery blood flow velocity (SMD = −1.36, 95% CI: −2.28, −0.49; p = 0.002) and GCS score (SMD = 1.24, 95% CI: 0.58, 1.89; p < 0.001) in the treatment group were significantly better than those in the control group. Conclusions Nimodipine is effective in the treatment of SAH, lowering incidence of adverse reactions and therefore improving the prognosis of patients.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2022) conducted a meta-analysis in Subarachnoid hemorrhage (SAH) (n=882). Nimodipine vs. Routine treatment was evaluated on Effective rate (OR 3.21, 95% CI 2.25-4.58, p=<0.001). Nimodipine significantly increased the effective rate of treatment (OR 3.21) and reduced the incidence of adverse reactions compared to routine treatment in patients with subarachnoid hemorrhage.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: